Congenital chylothorax (CCT) is the most prevalent form of pleural effusion in the first few days of life.[1](#ped412013-bib-0001){ref-type="ref"} It is a rare condition that results from thoracic duct damage with chyle leakage from the lymphatic system into the pleural space, with complications including malnutrition, immunosuppression, and respiratory distress,[2](#ped412013-bib-0002){ref-type="ref"} resulting in complicated clinical course and high mortality. The medium‐chain triglycerides formulas or total parenteral nutrition, octreotide, and surgical interventions are main clinical choices for treatment. However, information about the clinical course and the experience of treatments in infants with CCT are based mainly on data from single‐ and multicenter case series, and medical and surgical interventions lack substantial evidence.

The report of the five cases with CCT by Healy et al[3](#ped412013-bib-0003){ref-type="ref"} showed various clinical pictures of this rare disease and answered certain questions related to treatment and prognosis of the disease while larger cohorts have rarely been reported. No evidence‐based management guidelines have been available for infants with chylothorax yet. Recommendations for when to pursue surgical intervention in infants with chylothorax vary;[4](#ped412013-bib-0004){ref-type="ref"}, [5](#ped412013-bib-0005){ref-type="ref"} interestingly, Healy et al\'s report suggests that octreotide showed some effect and therefore might become an important therapeutic approach for CCT even in the setting of chyle volume outputs greater than prior proposed thresholds for surgery. This case series adds experience of successful octreotide use in CCT complicated with pulmonary hypertension, which was a potential side effect of chylothorax reported previously. However, octreotide use per se is also controversial. Systematic review has not shown clear benefit of octreotide in patients with chylothorax of both congenital and surgical etiologies,[6](#ped412013-bib-0006){ref-type="ref"} although some retrospective studies as well as this one reported its efficacy in reducing pleural chylous effusion.[7](#ped412013-bib-0007){ref-type="ref"} Performing prospective, multicenter clinical study with large sample size and sharing experiences might help to achieve evidence‐based treatment for this disease.

On the other hand, much more attention should be paid to diagnosis, treatment and prevention of congenital, and equally or more importantly, acquired chylothorax, and diseases of other parts of the body caused by abnormal lymphatic circulation, including those caused by nosocomial (medical, surgical) or other reasons. Although the five cases of CCT were reported from an NICU, the diseases caused by problems of lymphatic circulation may involve multiple specialties and subspecialties, including pediatric internal medicine, surgery, pulmonology, dermatology, oncology, infectious diseases etc. We hope pediatricians and doctors working at many different fields would consider and pay attention to diseases caused by lymph duct problems. We expect that pediatricians at Beijing Children\'s Hospital will soon start doing some substantial investigation in this field.
